Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This medtech company is among the most dominant in the world.

This Powerful Dividend-Paying Stock Hit Its 52-Week Low. Should You Buy Before 2022 Ends?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Why Is Medtronic (MDT) Down 2.4% Since Last Earnings Report?

This medical technology-focused stock offers income investors a 3.6% dividend yield.

Here's Why This Great Dividend Stock Is a Buy

Enterprise Products Partners

Lowe's

Pfizer

Verizon

The end of the year is often a time for investors to buy and sell stocks and clean up their portfolios. Some investors allocate excess cash to new investments or add to existing holdings.

5 Stocking Stuffer Stocks for Christmas 2022

Abbott Labs

We believe that Abbott stock and Medtronic stock in the medical devices industry will likely give similar returns over the next three years. Although Abbott is trading at a higher valuation of 4.2x trailing revenues, compared to 3.

Pick Either Abbott Stock Or Its Industry Peer – Both Are Likely To Offer Similar Returns

Costco

Generac Holdings

NextEra Energy

Tesla

This article looks at five stocks that are down significantly in 2022 but give investors reason to believe there could be a turnaround story in 2023

5 Down But Not Out Stocks To Watch For 2023

Medtronic's Hugo RAS system is designed to be used in Expand URO U.S. clinical trial study for urologic surgical procedures.

Medtronic (MDT) Enrolls 1st Patient Trial for Hugo RAS System

Expand URO is a prospective, multi-center, single-arm study to evaluate the safety and performance of the Hugo™ RAS system for urologic procedures DUBLIN , Dec. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo™ robotic-assisted surgery (RAS) system. The robotic-assisted prostatectomy procedure was performed by Dr. Michael R.

Medtronic announces first patient enrolled in U.S. clinical trial for Hugo™ robotic-assisted surgery system

General Electric

Siemens Healthineers AG

Siemens Healthineers AG and General Electric Co's healthcare business are weighing a potential acquisition of two units being spun off by Medtronic Plc, Bloomberg news reported on Thursday, citing people familiar with the matter.

Siemens Healthineers, GE Healthcare eye Medtronic units - Bloomberg News

Strong environmental, social, and governance (ESG) management and performance result in continued inclusion on the Dow Jones Sustainability World Index DUBLIN , Dec. 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its continued inclusion in the Dow Jones® Sustainability World Index (DJSI) as one of the world's leading companies for sustainability. The DJSI World Index includes global sustainability leaders that are identified by S&P Dow Jones Indices based on their performance in the S&P Global Corporate Sustainability Assessment across a variety of sustainability criteria, including long-term economic performance, environmental stewardship, social responsibility, and corporate governance.

Medtronic named as a leading sustainability company

HCA Healthcare

It pays to be prepared, and these stocks could help you.

2 Stocks to Buy if There Is a Recession Next Year

Johnson & Johnson

Both of these stocks have characteristics that make for stable, long-term investments.

2 Dividend Aristocrats to Buy and Hold Until You Retire

Medtronic PLC ( MDT , Financial) is an attractive stock for investors looking for solid and profitable options. The broad portfolio of medical devices, medications and services has been the driving force of the company's success.

Medtronic: Income Investor's Delight Available at a Discount

DUBLIN , Dec. 8, 2022 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 8, 2022, approved the fiscal year 2023 third quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2022.

Medtronic announces cash dividend for third quarter of fiscal year 2023

Medtronic is a durable healthcare products company with a longstanding history of success and a sound business model. Market sentiment has been highly negative around the stock based on what I see as being temporary headwinds.

Medtronic: Buy The Dip And Start The DRIP

3.6% Dividend Yield. Dividend increased 8% last fiscal year. High 80% cash flow conversion with 50% Free Cash Flow (FCF) shareholder return target.

Medtronic Is A Compelling 3.6% Dividend Grower

SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN , Dec. 5, 2022 /PRNewswire/ -- Medtronic (NYSE:MDT) today announced the completion of enrollment and final treatment in the SPHERE Per-AF Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial designed to evaluate the safety and effectiveness of the first-of-its kind Sphere-9™ pulsed field (PF) and radiofrequency (RF) ablation, and high density (HD) mapping catheter with the Affera cardiac mapping and navigation platform for the treatment of persistent atrial fibrillation (AF). The investigational Medtronic technology includes the Affera mapping/navigation platform, designed to improve efficiencies by enabling intuitive HD mapping to diagnose arrhythmias and treat patients with one catheter.

Medtronic completes enrollment in pivotal trial evaluating first-of-its-kind pulsed field ablation catheter for patients with atrial fibrillation

Merck

Suncor Energy

Exxon Mobil

As the SPX has risen to 4,000, some stocks have become outrageously expensive. Others, in the same sector, are still very cheap.

2 Urgent Dividend Sells And 2 Blue Chip Replacements To Increase Your Income

Best Buy

Comcast

Intel

Morgan Stanley

Truist Financial

T. Rowe Price Group

Texas Instruments

I present my top 10 High Yield dividend stocks that are poised to offer strong future returns. The annualized rate of return for this watchlist is 16.68% over the past 25 months.

My Top 10 High Yield Dividend Stocks For December 2022

Devon Energy

Home Depot

Kroger

McDonald's

With the holiday season upon us, investors may want to focus largely on dividend stocks to buy. While growth-oriented names provide the most excitement, market participants must acknowledge reality.

7 Excellent Dividend Stocks to Buy for the Holiday Season

Medtronic plc (NYSE:MDT ) 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 5:10 PM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Okay. Thanks, everyone for joining us.

Medtronic plc (MDT) 5th Annual Evercore ISI HealthCONx Conference (Transcript)

Arbor Realty Trust

Amcor Plc

Ares Management

Franklin Resources

Essex Property Trust

eXp World Holdings Inc

Innovative Industrial Properties

Kinder Morgan

Leggett & Platt

Main Street Capital

Magellan Midstream Partners

Philip Morris

Sanofi

Starwood Property

Walgreens

A February 2, 2022, Kiplinger Today special report headlined, "Potent Picks to Profit in 2022,” featured 97 dividend-fetching stocks from 118 in that article. Here is YCharts 11/25/22 update. Article titles were: '65 Best Dividends', '15 Value Stocks', '15 Best Mid-Caps', '10 European Plays', '9 High Yields', '6 Sturdy Defensive Stocks.'

12 Potent Picks Are December's Ideal Dividend Buys

The recent fall can be attributed to the Q2FY23 results the company reported yesterday, with revenue falling below and earnings above our estimates.

Should You Buy Medtronic Stock At $80?

Albemarle

Clorox

Ecolab

NOBL gained 10.31% in October, which brings the Fund's return for the year to a loss of 8.96%. Thus far this month, through November 22nd, the dividend aristocrat ETF is up 6.52%, bringing its year-to-date return to -3.03%.

My Best Dividend Aristocrats For December 2022

News for Medtronic Stock (MDT)